Media releases
- June
- 17-Jun-2013 Three Scientists to Receive Prestigious Novartis Prizes for Immunology at 15th International Congress of Immunology »
- 16-Jun-2013 Novartis drug Jakavi® improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease »
- 10-Jun-2013 Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis »
- 05-Jun-2013 New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis »
- 03-Jun-2013 Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer »
- 02-Jun-2013 Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in HER2 positive advanced breast cancer »
- May
- 31-May-2013 Lucentis® receives positive opinion for patients with myopic choroidal neovascularization showing vision gains with only two injections »
- 29-May-2013 World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease »
- 29-May-2013 Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA »
- 23-May-2013 Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues »
- 21-May-2013 New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations »
- 21-May-2013 Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement »
- 17-May-2013 Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer »
- 17-May-2013 Novartis wins GBCHealth Business Action on Health Award for social ventures initiative »
- 10-May-2013 Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis »
- 08-May-2013 Real-world data at ARVO highlight transformational outcomes seen with Lucentis®, including lower injection frequency than in original clinical trials »
- April
- 25-Apr-2013 Novartis signs on to support Malaria No More's Power of One campaign to stride towards a future without malaria »
- 24-Apr-2013 Novartis discloses compensation for new Chairman and Chairman ad-interim »
- 24-Apr-2013 Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth »
- 23-Apr-2013 Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients »
- 19-Apr-2013 Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta blocker-free, fixed-combination therapy for glaucoma patients »
- 01-Apr-2013 Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India »
- March
- 26-Mar-2013 Novartis confirms growing Gilenya® clinical and real-world experience as number of patients treated increases to over 63,000 »
- 21-Mar-2013 New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies »
- 18-Mar-2013 Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole »
- 15-Mar-2013 Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer »
- 13-Mar-2013 Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis »
- 01-Mar-2013 Novartis receives EU approval for Ilaris® in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments »
- February
- 28-Feb-2013 Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa »
- 24-Feb-2013 Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1] »
- 22-Feb-2013 Shareholders approve all resolutions proposed by Novartis Board of Directors - Dr. Joerg Reinhardt to succeed as Chairman following transition period »
- 19-Feb-2013 Novartis Board of Directors and Dr. Daniel Vasella agree to cancel the non-compete agreement and all related compensation; Decision taken to address concerns of stakeholders »
- 15-Feb-2013 Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients »
- January
- 23-Jan-2013 Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia »
- 23-Jan-2013 Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013 »
- 22-Jan-2013 Novartis receives EU approval for Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe »
- 18-Jan-2013 Novartis receives positive CHMP opinion for Ilaris® to treat patients whose acute gouty arthritis cannot be managed with standard of care »
- 18-Jan-2013 Jetrea(TM) receives positive CHMP opinion, would become the first drug to treat sight-threatening vitreomacular traction and macular hole »
- 17-Jan-2013 Novartis makes progress in the fight to eliminate leprosy worldwide »
- 14-Jan-2013 Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero® to help provide broad protection to infants against MenB »
- 11-Jan-2013 Phase III data in The Lancet show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC »
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
